Evidence map›Paper›PMID 42463640›Full record

ArticleTranslational psychiatry2026

Disruption of Reelin signaling in a dual-hit mouse model of schizophrenia: impact of postnatal Δ9-tetrahydrocannabinol exposure in a maternal immune activation model.

Celia Martín-Cuevas, Víctor Darío Ramos-Herrero, Álvaro Flores-Martínez, Irene González-Recio, María Luz Martínez-Chantar, Juan Carlos Leza, J Javier Meana, Benedicto Crespo-Facorro, Ana C Sánchez-Hidalgo

Abstract read
In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Celia Martín-CuevasInstituto de Biomedicina de Sevilla (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Manuel Siurot AV, 41013, Seville, Spain.
Víctor Darío Ramos-Herrero *Instituto de Biomedicina de Sevilla (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Manuel Siurot AV, 41013, Seville, Spain.
Álvaro Flores-Martínez *Instituto de Biomedicina de Sevilla (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Manuel Siurot AV, 41013, Seville, Spain.
Irene González-RecioLiver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio (Bizkaia), Spain; Center for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Bizkaia, Spain.
María Luz Martínez-ChantarLiver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio (Bizkaia), Spain; Center for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Bizkaia, Spain.ORCID http://orcid.org/0000-0002-6446-9911
Juan Carlos LezaSpanish Network for Research in Mental Health (CIBERSAM, ISCIII), Monforte de Lemos AV, 3-5, 28029, Madrid, Spain.
J Javier MeanaSpanish Network for Research in Mental Health (CIBERSAM, ISCIII), Monforte de Lemos AV, 3-5, 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-7913-6714
Benedicto Crespo-FacorroInstituto de Biomedicina de Sevilla (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Manuel Siurot AV, 41013, Seville, Spain. bcrespo@us.es.ORCID http://orcid.org/0000-0003-0033-7132
Ana C Sánchez-HidalgoInstituto de Biomedicina de Sevilla (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Manuel Siurot AV, 41013, Seville, Spain.

Funding

Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia) P20_00811Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PI-0014-2022Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2019-109405RB-I00/AEI/10.13039/501100011033Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) AC23_2/00034Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI22/01379
6 · The paper itself

Abstract

Since the discovery of the first antipsychotic, pharmacological treatment of schizophrenia (SCZ) has primarily relied on dopamine D2 receptor antagonist. However, variability in treatment responses highlights the need for novel biomarkers and therapeutics targets. Here, we developed a dual-hit mouse model combining maternal immune activation (MIA) induced by polyinosinic-polycytidylic acid (Poly(I:C)) with adolescent exposure to Δ9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis. We evaluated the face validity of this model and investigated potential alterations in the Reelin signaling pathway. Behaviorally, the dual-hit condition induced alterations across multiple domains, including social deficits and increased repetitive behavior, consistent with schizophrenia-relevant phenotypes. These effects were particularly evident in males, supporting a domain-specific interaction between prenatal immune activation and adolescent THC exposure rather than a uniform synergistic effect. Structurally, THC exposure was associated with reduced cortical thickness, while dual-hit mice showed decreased dendritic spine density in the prefrontal cortex and hippocampus. At the molecular level, Reelin pathway alterations were observed in a sex-dependent manner. In males, reduced Reelin levels were most prominent following THC exposure alone, whereas in females, a general reduction was observed across treatment groups. Additionally, a decrease in the number of Reelin-positive cells was detected. These findings indicate that adolescent THC exposure is a major driver of Reelin alterations, with prenatal immune activation potentially modulating this effect. Overall, this model recapitulates selective SCZ-relevant phenotypes and highlights the complex, domain-specific interaction between environmental risk factors. Our results support a role for Reelin signaling alterations in SCZ-related processes, while emphasizing that their contribution depends on the nature and timing of environmental insults. Abbreviations: Poly(I:C): polyinosinic-polycytidylic acid; THC: Δ9-tetrahydrocannabinol; GD: gestational day; PD: postnatal day; PFC: prefrontal cortex; HP: hippocampus. Created with Biorender.com.

Indexed as

Cell Adhesion Molecules, NeuronalDronabinolExtracellular Matrix ProteinsNerve Tissue ProteinsPrenatal Exposure Delayed EffectsSchizophreniaSerine EndopeptidasesSignal TransductionAnimalsBehavior, AnimalDendritic SpinesDisease Models, AnimalFemaleHippocampusMaleMiceCell Adhesion Molecules, NeuronalDronabinolExtracellular Matrix ProteinsNerve Tissue ProteinsPoly I-CReelin ProteinReln protein, mouseSerine Endopeptidases

Identifiers

PMID42463640
PMCPMC13655088

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.